APA: Inhaled Agent Loxapine Effective in Acute Agitation (CME/CE)
SAN FRANCISCO (MedPage Today) — The antipsychotic drug loxapine, delivered with an investigational inhaler, quickly relieved acute agitation in patients with schizophrenia and bipolar disorder in separate phase III trials, researchers said.
Similar Posts on depression:
- FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
- APA: Novel Antipsychotic Promising for Schizophrenia (CME/CE)
- FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
- APA: Nicotine Patch May Soothe Schizophrenic Smokers (CME/CE)
- Patients in Trials of Depression Drugs Called Unrepresentative (CME/CE)
- Cognitive Therapy Helps Seniors Fight Anxiety
- FDA Approves Iloperidone for Schizophrenia
- AAN: Gene Therapy Puzzling in Diabetic Neuropathy
- AAN: Gene Therapy Puzzling in Diabetic Neuropathy Trial
- Patients in Trials of Depression Drugs Called Unrepresentative (CME/CE)
